1 |
王 晶,陈 曦,孙 宁,等. COPD合并阻塞性睡眠呼吸暂停低通气综合征的临床分析[J/CD]. 中华肺部疾病杂志(电子版), 2022, 15(6): 819-821.
|
2 |
MacLeod Mairi, Papi Alberto, Contoli Marco, et al. Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact[J]. Respirology, 2021, 26(6):532-551.
|
3 |
Halpin David MG, Criner Gerard J, Papi Alberto, et al. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease[J]. Am J Respir Crit Care Med, 2021, 203(1): 24-36.
|
4 |
Singh Dave, Agusti Alvar, Anzueto Antonio, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019[J]. Eur Respir J, 2019, 53(5): 1900164.
|
5 |
Mathioudakis Alexander G, Janssens Wim, Sivapalan Pradeesh, et al. Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits[J]. Thorax, 2020, 75(6): 520-527.
|
6 |
Vogelmeier Claus F, Román-Rodríguez Miguel, Singh Dave, et al. Goals of COPD treatment: Focus on symptoms and exacerbations[J]. Respir Med, 2020, 166(1): 105938.
|
7 |
Vestbo Jrgen, Papi Alberto, Corradi Massimo, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial[J]. Lancet, 2017, 389(10082): 1919-1929.
|
8 |
Roche Nicolas, Antoniadis Anestis, Hess David, et al. Are there specific clinical characteristics associated with physician′s treatment choices in COPD[J]. Respir Res, 2019, 20(1): 189.
|
9 |
Papi Alberto, Luppi Fabrizio, Franco Francesca, et al. Pathophysiology of exacerbations of chronic obstructive pulmonary disease[J]. Proc Am Thorac Soc, 2006, 3(3): 245-251.
|
10 |
Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial[J]. Eur Respir J, 2007, 29(5): 906-913.
|
11 |
Bafadhel Mona, McKenna Susan, Terry Sarah, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers[J]. Am J Respir Crit Care Med, 2011, 184(6): 662-671.
|
12 |
慢性阻塞性肺疾病诊治指南(2013年修订版)[J/CD]. 中国医学前沿杂志(电子版), 2014, 6(2): 67-80.
|
13 |
Gillissen A, Paparoupa M, Frings D, et al. [Inhaled triple therapy in severe chronic obstructive pulmonary disease (COPD)][J]. Pneumologie, 2018, 72(12): 832-842.
|
14 |
Wu Chia-Tung, Li Guo-Hung, Huang Chun-Ta, et al. Acute exacerbation of a chronic obstructive pulmonary disease prediction system using wearable device data, machine learning, and deep learning: Development and cohort study[J]. JMIR Mhealth Uhealth, 2021, 9(5): e22591.
|
15 |
Kunadharaju Rajesh, Sethi Sanjay. 2 Treatment of acute exacerbations in chronic obstructive pulmonary disease[J]. Clin Chest Med, 2020, 41(3): 439-451.
|
16 |
中华医学会呼吸病学分会慢性阻塞性肺疾病学组,中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南(2021年修订版)[J]. 中华结核和呼吸杂志,2021, 44(3): 170-205.
|
17 |
Averell Carlyne M, Laliberté François,Duh Mei Sheng, et al. Characterizing real-world use of tiotropium in asthma in the USA[J]. J Asthma Allergy, 2019, 12(1): 309-321.
|
18 |
Long Huanyu, Xu Hongxuan, Janssens Jean-Paul, et al. Single-inhaler triple vs single-inhaler dual therapy in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized control trials[J]. Respir Res, 2021, 22(1): 209.
|
19 |
Chen Stephanie, Miravitlles Marc, Rhee Chin Kook, et al. Patients with chronic obstructive pulmonary disease and evidence of eosinophilic inflammation experience exacerbations despite receiving maximal inhaled maintenance therapy[J]. Int J Chron Obstruct Pulmon Dis, 2022, 17(1): 2187-2200.
|
20 |
Sibani Maitha Al, Alawi Abdullah Al, Aghbari Jamal Al. Elevated peripheral blood eosinophils during acute exacerbation of chronic obstructive pulmonary disease: Prevalence and clinical significance[J]. Sultan Qaboos Univ Med J, 2022, 22(3): 339-342.
|
21 |
Pascoe Steven, Barnes Neil, Brusselle Guy, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial[J]. Lancet Respir Med, 2019, 7(9): 745-756.
|
22 |
Oshagbemi Olorunfemi A, Franssen Frits ME, Braeken Dionne CW, et al. Blood eosinophilia, use of inhaled corticosteroids, and risk of COPD exacerbations and mortality[J]. Pharmacoepidemiol Drug Saf, 2018, 27(11): 1191-1199.
|
23 |
Antus Balazs, Barta Imre. Blood eosinophils and exhaled nitric oxide:Surrogate biomarkers of airway eosinophilia in stable COPD and exacerbation[J]. Biomedicines, 2022, 10(9): 2128.
|
24 |
DiSantostefano Rachael L, Hinds David, Van Le Hoa, et al. Relationship between blood eosinophils and clinical characteristics in a cross-sectional study of a US population-based COPD cohort[J]. Respir Med, 2016, 112(1): 88-96.
|
25 |
Mkorombindo Takudzwa, Dransfield Mark T. Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease[J]. Int J Chron Obstruct Pulmon Dis, 2019, 14(1): 1779-1787.
|
26 |
Singh Dave, Kolsum Umme, Brightling Chris E, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics[J]. Eur Respir J, 2014, 44(6): 1697-1700.
|